Healthcare | March 20, 2024
Aster’s India and GCC business separation nearing completion
The plan essentially was to separate Aster’s India and GCC businesses to unlock long-term value
The plan essentially was to separate Aster’s India and GCC businesses to unlock long-term value
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
The WHO GMP approved vertically integrated ONCOLOGY unit of SAKAR has been selling products nationally since few quarters
Varenicline is indicated for smoking cessation in adults
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Minzoya Tablets are indicated for use by females of reproductive potential to prevent pregnancy
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
Subscribe To Our Newsletter & Stay Updated
